Table 1.
Baseline patient characteristics.
| Variables | n = 28 |
|---|---|
| Female, n (%) | 19 (67.9%) |
| Age, years | 64.8 ± 12.1 |
| WHO functional class, I/II/III/IV | 0/8/16/4 |
| 6MWD, m | 303.0 ± 91.9 |
| Heart rate, beat/min | 72.0 ± 8.4 |
| Systolic PAP, mm Hg | 61.1 ± 18.8 |
| Diastolic PAP, mm Hg | 19.7 ± 5.8 |
| Mean PAP, mm Hg | 34.2 ± 10.4 |
| PCWP, mm Hg | 7.9 ± 2.4 |
| RAP, mm Hg | 4.8 ± 2.3 |
| CO, L/min | 4.1 ± 1.3 |
| PVR, dyne/s/cm5 | 574.4 ± 316.7 |
| BNP, pg/ml | 160.4 ± 233.4 |
| Warfarin, n (%) | 28 (100) |
| Administration of pulmonary vasodilators, n (%) | 20 (71.4) |
| PGI2, n (%) | 5 (17.9) |
| ERAs, n (%) | 16 (57.1) |
| PDE-5 inhibitors, n (%) | 6 (21.4) |
| sGC | 1 (3.6%) |
Values are mean ± SD or percent. BNP, brain natriuretic peptide; CO, cardiac output; ERA, endothelin receptor antagonist; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PDE-5, phosphodiesterase type 5; PGI2, prostaglandin analog; PVR, pulmonary vascular resistance; RAP, right atrial pressure; sGC, soluble guanylate cyclase activator; WHO, World Health Organization; 6MWT, 6 min walk test.